HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling.

Abstract
Docetaxel-based chemotherapy is a standard-of-care treatment for metastatic prostate cancer, and chemoresistance remains a major challenge in clinical practice. Recent studies have demonstrated that circular RNAs (circRNA) play critical roles in the development and progression of prostate cancer. However, the biological roles and potential functions of circRNAs in mediating docetaxel-resistant prostate cancer have yet to be well elucidated. In this study, we analyzed the expression profiles of circRNAs in docetaxel-resistant and -sensitive prostate cancer cells through RNA sequencing and found that expression of circARHGAP29 was significantly upregulated in docetaxel-resistant cell lines and clinical samples. Ectopic expression of circARHGAP29 triggered docetaxel resistance and aerobic glycolysis in prostate cancer cells, which was reduced by silencing circARHGAP29. Moreover, eukaryotic initiation factor 4A3, which bound the back-spliced junction site and the downstream flanking sequence of circARHGAP29, induced cyclization and cytoplasmic export of circARHGAP29. circARHGAP29 increased the stability of lactate dehydrogenase A (LDHA) mRNA by strengthening its interaction with insulin-like growth factor 2 mRNA-binding protein 2, leading to enhanced glycolytic metabolism. In addition, circARHGAP29 interacted with and stabilized c-Myc mRNA and protein, which further increased LDHA expression by facilitating its transcription. These findings reveal the crucial function of circARHGAP29 in prostate cancer glycolysis by increasing and stabilizing LDHA mRNA, providing a promising therapeutic target in docetaxel-resistant prostate cancer.
SIGNIFICANCE:
Upregulation of a novel circRNA, circARHGAP29, promotes docetaxel resistance and glycolytic metabolism, suggesting it could be a prognostic biomarker and therapeutic target in chemoresistant prostate cancer.
AuthorsXingkang Jiang, Shanqi Guo, Shuo Wang, Yangyi Zhang, Haojie Chen, Yong Wang, Ranlu Liu, Yuanjie Niu, Yong Xu
JournalCancer research (Cancer Res) Vol. 82 Issue 5 Pg. 831-845 (Mar 01 2022) ISSN: 1538-7445 [Electronic] United States
PMID34965937 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2021 American Association for Cancer Research.
Chemical References
  • IGF2BP2 protein, human
  • RNA, Circular
  • RNA, Messenger
  • RNA-Binding Proteins
  • Docetaxel
  • Lactate Dehydrogenase 5
  • Eukaryotic Initiation Factor-4A
  • EIF4A3 protein, human
  • DEAD-box RNA Helicases
Topics
  • Cell Line, Tumor
  • Cell Proliferation
  • DEAD-box RNA Helicases (genetics)
  • Docetaxel (pharmacology)
  • Eukaryotic Initiation Factor-4A (genetics)
  • Gene Expression Regulation, Neoplastic
  • Glycolysis (genetics)
  • Humans
  • Lactate Dehydrogenase 5
  • Male
  • Prostatic Neoplasms (pathology)
  • RNA, Circular (genetics)
  • RNA, Messenger (genetics)
  • RNA-Binding Proteins (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: